16 completed, 9 unknown, 8 recruiting, 5 terminated. 43 Phase 2, 8 Phase 1, 5 Phase 3.
Follow Stomach Cancer: new trials by email Literature Review of Stomach Cancer trials Research Report on Stomach Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors 3H-10000 - Lung Cancer, Stomach Cancer | Phase 1 / Phase 2 | Recruiting | 3H Pharmaceuticals Co., Ltd. | 170 | 2026-01-04 | 2026-01-21 |
| Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA Ivonescimab, 5-Fluorouracil, Oxaliplatin - Stomach Cancer Stage IV, Esophagus Cancer | Phase 2 | Recruiting | Massachusetts General Hospital | 40 | 2025-10-10 | 2026-08-28 |
| Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer Docetaxel, Oxaliplatin, Leucovorin - Gastric Cancer, Stomach Cancer | Phase 2 / Phase 3 | Recruiting | Ukrainian Society of Clinical Oncology | 150 | 2025-03-25 | 2025-05-06 |
| Avutometinib and Defactinib in Diffuse Gastric Cancer Avutometinib, Defactinib - Gastric Cancer, Stomach Cancer | Phase 2 | Recruiting | Ryan H. Moy, MD, PhD | 27 | 2024-10-28 | 2026-11-06 |
| TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamid, Fludarabine - Stomach Cancer, Stomach Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 75 | 2024-09-10 | 2024-11-12 |
| Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer Paclitaxel Polymeric Micelles for Injection - Pancreatic Adenocarcinoma, Cholangiocarcinoma | Phase 2 | Recruiting | Liu Huang | 25 | 2023-11-28 | 2025-06-03 |
| A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) IMU-131, Ramucirumab plus Paclitaxel, Pembrolizumab - Gastric Cancer, Cancer of Stomach | Phase 2 | Terminated | Imugene Limited | 7 | 2022-08-17 | 2025-05-11 |
| KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection - Stomach Cancer | Phase 2 / Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | 286 | 2022-04-07 | 2023-12-19 |
| XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma Anlotinib hydrochloride capsule, Penpulimab Injection, XELOX - Carcinoma, Gastrointestinal Diseases | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 80 | 2022-03-16 | 2023-11-07 |
| Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC Tirelizumab, Trastuzumab, Docetaxel - Stomach Cancer | Phase 2 | Unknown | The First Affiliated Hospital of Zhengzhou University | 67 | 2021-12-01 | 2023-04-25 |
| Docetaxel and Irinotecan in Gastric Cancer Docetaxel, Irinotecan - Stomach Cancer, Gastric Cancer | Phase 2 | Completed | Menoufia University | 32 | 2021-03-05 | 2024-01-30 |
| Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC) PIPAC+SOX+OLAPARIB - Stomach Cancer, Gastric Cancer | Phase 1 / Phase 2 | Unknown | Ruijin Hospital | 30 | 2020-12-01 | 2020-06-01 |
| Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer Alpelisib, Paclitaxel - Solid Tumor, Stomach Cancer | Phase 1 / Phase 2 | Unknown | Seoul National University Bundang Hospital | 55 | 2020-09-01 | 2021-08-24 |
| A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL) - Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms | Phase 1 / Phase 2 | Completed | Intima Bioscience, Inc. | 23 | 2020-05-15 | 2026-02-23 |
| An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Relatlimab + Nivolumab, Nivolumab, Paclitaxel - Gastric Cancer, Cancer of the Stomach | Phase 2 | Withdrawn | Bristol-Myers Squibb | 2019-10-31 | 2020-05-19 | |
| AZD8186 and Paclitaxel in Advanced Gastric Cancer AZD8186 in combination with paclitaxel - Solid Tumor, Stomach Cancer | Phase 1 / Phase 2 | Unknown | Seoul National University Bundang Hospital | 49 | 2019-05-14 | 2019-06-28 |
| A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation Paclitaxel, Carboplatin, Dexamethasone - Gastric Cancer, Stomach Cancer | Phase 2 | Unknown | Icahn School of Medicine at Mount Sinai | 29 | 2018-12-03 | 2023-11-14 |
| Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients Ramucirumab, Paclitaxel - Stomach Cancer, Stomach Neoplasm | Phase 2 | Unknown | Federation Francophone de Cancerologie Digestive | 112 | 2018-11-16 | 2024-07-08 |
| Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab - Gastro Esophageal Junction Cancer, Stomach Cancer | Phase 2 | Active not recruiting | University of Kansas Medical Center | 40 | 2018-06-27 | 2023-05-19 |
| Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA) Atezolizumab, Capecitabine, Oxaliplatin - Stomach Cancer, Gastro Esophageal Junction Cancer | Phase 2 | Active not recruiting | The Netherlands Cancer Institute | 20 | 2018-03-07 | 2026-09-30 |
Showing 20 of 43. Sign in to see all of them.
Stomach Neoplasms (43) · Esophageal Neoplasms (13) · Adenocarcinoma (4) · Gastrointestinal Neoplasms (4) · Colonic Neoplasms (3) · Gallbladder Neoplasms (3) · Pancreatic Neoplasms (3) · Breast Neoplasms (2) · Cholangiocarcinoma (2) · Gastrointestinal Stromal Tumors (2) · Lung Neoplasms (2) · Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Biliary Tract Neoplasms (1) · Carcinoma (1)
Digestive System Neoplasms (43) · Neoplasms by Site (43) · Stomach Diseases (43) · Digestive System Diseases (42) · Gastrointestinal Diseases (42) · Neoplasms (41) · Gastrointestinal Neoplasms (39) · Head and Neck Neoplasms (14) · Esophageal Diseases (13) · Neoplasms by Histologic Type (8) · Neoplasms, Glandular and Epithelial (7) · Carcinoma (6) · Intestinal Diseases (5) · Intestinal Neoplasms (5) · Colonic Diseases (4)
Oxaliplatin (12) · Docetaxel (8) · Paclitaxel (8) · Capecitabine (6) · Fluorouracil (6) · Irinotecan (6) · Leucovorin (5) · Ramucirumab (5) · pembrolizumab (5) · Bevacizumab (3) · Cisplatin (3) · S 1 (combination) (3) · Trastuzumab (3) · Carboplatin (2) · Cyclophosphamide (2)
Dana-Farber Cancer Institute (3) · Bristol-Myers Squibb (2) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (2) · NYU Langone Health (2) · Seoul National University Bundang Hospital (2) · 3H Pharmaceuticals Co., Ltd. (1) · Asan Medical Center (1) · Eli Lilly and Company (1) · Essen Biotech (1) · Federation Francophone de Cancerologie Digestive (1) · Heikki Joensuu (1) · Icahn School of Medicine at Mount Sinai (1) · Imugene Limited (1) · Intima Bioscience, Inc. (1) · Kangbuk Samsung Hospital (1)
United States (18) · China (8) · South Korea (8) · Germany (3) · Australia (2) · Canada (2) · Italy (2) · Taiwan (2) · Argentina (1) · Brazil (1) · Chile (1) · Colombia (1) · Egypt (1) · Finland (1) · France (1)
Salah-Eddin Al-Batran, Prof. Dr. (2) · Akos Czibere, MD, PhD (1) · Anders Johnsson, MD, PhD (1) · Birendra K Sah, PH D (1) · Chen Li, PH D (1) · Dingzhi Huang, M.D. (1) · Dong Hoe Koo, MD,PhD (1) · Emil Lou, MD, PhD (1) · Franco Muggia, MD (1) · Heikki Joensuu, MD (1) · Jaffer Ajani, MD (1)
PMID 35623069, PMID 20354452, PMID 22479375, PMID 24380989, PMID 27765757, PMID 32653053, PMID 34172290, PMID 35709415, PMID 36883420, PMID 37036671, PMID 37104758, PMID 38022553, PMID 38191613, PMID 40315882, PMID 40673842
2018 (1)